Journal ArticleDOI
Diagnostic criteria for multiple sclerosis.
Charles M. Poser,Vesna V. Brinar +1 more
TLDR
The history of clinical diagnostic criteria demonstrates the evolution from rather tentative classifications of restricted value to the more elaborate 1983 scheme which incorporates some laboratory procedures under the rubric paraclinical tests as well as a new category based on the presence of specific abnormalities of the cerebrospinal fluid (CSF).About:
This article is published in Clinical Neurology and Neurosurgery.The article was published on 2001-04-01. It has received 1902 citations till now.read more
Citations
More filters
Journal ArticleDOI
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
Chris H. Polman,Stephen C. Reingold,Brenda Banwell,Michel Clanet,Jeffrey A. Cohen,Massimo Filippi,Kazuo Fujihara,Eva Havrdova,Michael Hutchinson,Ludwig Kappos,Fred D. Lublin,Xavier Montalban,Paul L. O’Connor,Magnhild Sandberg-Wollheim,Alan J. Thompson,Emmanuelle Waubant,Brian G. Weinshenker,Jerry S. Wolinsky +17 more
TL;DR: These revisions simplify the McDonald Criteria, preserve their diagnostic sensitivity and specificity, address their applicability across populations, and may allow earlier diagnosis and more uniform and widespread use.
Journal ArticleDOI
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
Alan J. Thompson,Brenda Banwell,Frederik Barkhof,Frederik Barkhof,William M. Carroll,Timothy Coetzee,Giancarlo Comi,Jorge Correale,Franz Fazekas,Massimo Filippi,Mark S. Freedman,Kazuo Fujihara,Steven L. Galetta,Hans-Peter Hartung,Ludwig Kappos,Fred D. Lublin,Ruth Ann Marrie,Aaron E. Miller,David Miller,Xavier Montalban,Xavier Montalban,Ellen M. Mowry,Per Soelberg Sørensen,Mar Tintoré,Anthony Traboulsee,Maria Trojano,Bernard M. J. Uitdehaag,Sandra Vukusic,Sandra Vukusic,Emmanuelle Waubant,Brian G. Weinshenker,Stephen C. Reingold,Jeffrey A. Cohen +32 more
TL;DR: The 2017 McDonald criteria continue to apply primarily to patients experiencing a typical clinically isolated syndrome, define what is needed to fulfil dissemination in time and space of lesions in the CNS, and stress the need for no better explanation for the presentation.
Journal ArticleDOI
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Ludwig Kappos,Ernst Wilhelm Radue,Paul O'Connor,Chris H. Polman,Reinhard Hohlfeld,Peter A. Calabresi,Krzysztof Selmaj,Catherine Agoropoulou,Malgorzata Leyk,Lixin Zhang-Auberson,Pascale Burtin +10 more
TL;DR: Both doses of oral fingolimod improved the relapse rate, the risk of disability progression, and end points on MRI and were superior to placebo with regard to MRI-related measures.
Journal ArticleDOI
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
Jeffrey A. Cohen,Frederik Barkhof,Giancarlo Comi,Hans Peter Hartung,Bhupendra Khatri,Xavier Montalban,Jean Pelletier,Ruggero Capra,Paolo Gallo,Guillermo Izquierdo,Klaus Tiel-Wilck,Ana de Vera,James Jin,Tracy Stites,Stacy Wu,Shreeram Aradhye,Ludwig Kappos +16 more
TL;DR: This trial showed the superior efficacy of oral fingolimod with respect to relapse rates and MRI outcomes in patients with multiple sclerosis, as compared with intramuscular interferon beta-1a.
Journal ArticleDOI
The spectrum of neuromyelitis optica
Dean M. Wingerchuk,Vanda A. Lennon,Claudia F. Lucchinetti,Sean J. Pittock,Brian G. Weinshenker +4 more
TL;DR: Data suggest that autoantibodies to aquaporin 4 derived from peripheral B cells cause the activation of complement, inflammatory demyelination, and necrosis that is seen in neuromyelitis optica.
References
More filters
Journal ArticleDOI
New diagnostic criteria for multiple sclerosis: guidelines for research protocols.
Charles M. Poser,Donald W. Paty,Labe C. Scheinberg,W I McDonald,F A Davis,George C. Ebers,Kenneth P. Johnson,William A. Sibley,Donald H. Silberberg,Wallace W. Tourtellotte +9 more
TL;DR: Today there is a need for more exact criteria than existed earlier in order to conduct therapeutic trials in multicenter programs, to compare epidemiological surveys, to evaluate new diagnostic procedures, and to estimate the activity of the disease process in MS.
Journal ArticleDOI
The Chronic Fatigue Syndrome: A Comprehensive Approach to Its Definition and Study
Keiji Fukuda,Sharon E. Straus,Ian B. Hickie,Michael Sharpe,James G. Dobbins,Anthony L. Komaroff +5 more
TL;DR: A conceptual framework and a set of research guidelines for use in studies of the chronic fatigue syndrome are developed that cover the clinical and laboratory evaluation of persons with unexplained fatigue; the identification of underlying conditions that may explain the presence of chronic fatigue; revised criteria for defining cases of the Chronic fatigue syndrome; and a strategy for dividing the chronic Fatigue syndrome and other unexplained cases of Chronic fatigue into subgroups.
Journal ArticleDOI
Chronic Fatigue Syndrome: A Working Case Definition
Gary P. Holmes,Jonathan E. Kaplan,Nelson M. Gantz,Anthony L. Komaroff,Lawrence B. Schonberger,Sharon E. Straus,James F. Jones,Richard E. Dubois,Charlotte Cunningham-Rundles,Savita Pahwa,Giovanna Tosato,Leonard S. Zegans,David T. Purtilo,Nathaniel A. Brown,Robert T. Schooley,Irena Brus +15 more
TL;DR: A new name is proposed for the chronic Epstein-Barr virus syndrome--the chronic fatigue syndrome--that more accurately describes this symptom complex as a syndrome of unknown cause characterized primarily by chronic fatigue.
Journal ArticleDOI
Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis
Lawrence Jacobs,Roy W. Beck,J H Simon,R. P. Kinkel,C. M. Brownscheidle,T J Murray,N. A. Simonian,P J Slasor,Alfred Sandrock +8 more
TL;DR: Starting treatment with interferon beta-1a at the time of a first demyelinating event is beneficial for patients with brain lesions on MRI that indicate a high risk of clinically definite multiple sclerosis.
Journal ArticleDOI
Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis.
George A. Schumacher,Gilbert Beebe,Robert F. Kibler,Leonard T. Kurland,John F. Kurtzke,Fletcher McDowell,Benedict Nagler,William A. Sibley,Wallace W. Tourtellotte,Thomas L. Willmon +9 more
TL;DR: Since its etiology and pathogenesis have eluded detection, it is not surprising that therapeutic attempts have been empiric and often unscientific.
Related Papers (5)
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
Chris H. Polman,Stephen C. Reingold,Brenda Banwell,Michel Clanet,Jeffrey A. Cohen,Massimo Filippi,Kazuo Fujihara,Eva Havrdova,Michael Hutchinson,Ludwig Kappos,Fred D. Lublin,Xavier Montalban,Paul L. O’Connor,Magnhild Sandberg-Wollheim,Alan J. Thompson,Emmanuelle Waubant,Brian G. Weinshenker,Jerry S. Wolinsky +17 more